Cyclooxygenase inhibitors protect d-galactosamine/lipopolysaccharide induced acute hepatic injury in experimental mice model

Food and Chemical Toxicology

Volumn 50, Issue 3-4, 2012, Pages 861-866

  Liong, Emily C ^a   Xiao, Jia ^a   Lau, Thomas Y H ^b   Nanji, Amin A ^c   Tipoe, George L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Acute liver injury; Cyclooxygenase inhibitor; Lipopolysaccharide; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA ACTIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; MESSENGER RNA; NIMESULIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CYCLOOXYGENASE 1 GENE; CYCLOOXYGENASE 2 GENE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME BLOOD LEVEL; GENE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INDUCIBLE NITRIC OXIDE SYNTHASE GENE; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR ALPHA GENE; UPREGULATION; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; BLOTTING, WESTERN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; GALACTOSAMINE; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED ICR; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84856422951     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2011.11.009     Document Type: Article

References (39)

1. Akima S., Kent A., Reynolds G.J., Gallagher M., Falk M.C. Indomethacin and renal impairment in neonates. Pediatr. Nephrol. 2004, 19:490-493.
2. Brouckaert P., Fiers W. Tumor necrosis factor and the systemic inflammatory response syndrome. Curr. Top. Microbiol. Immunol. 1996, 216:167-187.
3. Buck M., Zhang L., Halasz N.A., Hunter T., Chojkier M. Nuclear export of phosphorylated C/EBP[beta] mediates the inhibition of albumin expression by TNF-[alpha]. EMBO J. 2001, 20:6712-6723.
4. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., Simmons D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl Acad. Sci. USA 2002, 99:13926-13931.
5. Chen J.H., Tipoe G.L., Liong E.C., So H.S., Leung K.M., Tom W.M., Fung P.C., Nanji A.A. Green tea polyphenols prevent toxin-induced hepatotoxicity in mice by down-regulating inducible nitric oxide-derived prooxidants. Am. J. Clin. Nutr. 2004, 80:742-751.
6. Coombs R.C., Morgan M.E., Durbin G.M., Booth I.W., McNeish A.S. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch. Dis. Child. 1990, 65:1067-1071.
7. Cowan F. Indomethacin, patent ductus arteriosus, and cerebral blood flow. J. Pediatr. 1986, 109:341-344.
8. Decker K., Keppler D. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev. Physiol. Biochem. Pharmacol. 1974, 77:106.
9. Devaux Y., Seguin C., Grosjean S., de Talance N., Camaeti V., Burlet A., Zannad F., Meistelman C., Mertes P.M., Longrois D. Lipopolysaccharide-induced increase of prostaglandin E(2) is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase. J. Immunol. 2001, 167:3962-3971.
10. Ewaschuk J., Endersby R., Thiel D., Diaz H., Backer J., Ma M., Churchill T., Madsen K. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007, 46:841-850.
11. Foka P., Singh N.N., Salter R.C., Ramji D.P. The tumour necrosis factor-[alpha]-mediated suppression of the CCAAT/enhancer binding protein-[alpha] gene transcription in hepatocytes involves inhibition of autoregulation. The International Journal of Biochemistry & Cell Biology 2009, 41:1189-1197.
12. Garcia I., Miyazaki Y., Araki K., Araki M., Lucas R., Grau G.E., Milon G., Belkaid Y., Montixi C., Lesslauer W., et al. Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur. J. Immunol. 1995, 25:2401-2407.
13. Ghosh N., Chaki R., Mandal V., Mandal S.C. COX-2 as a target for cancer chemotherapy. Pharmacol. Rep. 2010, 62:233-244.
14. Giboney P.T. Mildly elevated liver transaminase levels in the asymptomatic patient. Am. Fam. Physician 2005, 71:1105-1110.
15. Gupta S.K., Bansal P., Bhardwaj R.K., Velpandian T. Comparative anti-nociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination. Pharmacol. Res. 2000, 41:657-662.
16. Jaeschke H., Gores G.J., Cederbaum A.I., Hinson J.A., Pessayre D., Lemasters J.J. Mechanisms of hepatotoxicity. Toxicol. Sci. 2002, 65:166-176.
17. Kalra B.S., Chaturvedi S., Tayal V., Gupta U. Evaluation of gastric tolerability, antinociceptive and antiinflammatory activity of combination NSAIDs in rats. Indian J. Dent. Res. 2009, 20:418-422.
18. Krakauer T. Molecular therapeutic targets in inflammation: cyclooxygenase and NF-kappaB. Curr. Drug Targets Inflamm. Allergy 2004, 3:317-324.
19. Lehmann V., Freudenberg M.A., Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and d-galactosamine-treated mice. J. Exp. Med. 1987, 165:657-663.
20. Levy M.M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., Cohen J., Opal S.M., Vincent J.L., Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 2003, 31:1250-1256.
21. Lin B.-R., Yu C.-J., Chen W.-C., Lee H.-S., Chang H.-M., Lee Y.-C., Chien C.-T., Chen C.-F. Green tea extract supplement reduces d-galactosamine-induced acute liver injury by inhibition of apoptotic and proinflammatory signaling. J. Biomed. Sci. 2009, 16:35.
22. Lu Y.C., Yeh W.C., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42:145-151.
23. Mariani L., Bonanomi L. Resistance of the guinea pig to indomethacin ulcerogenesis. Toxicol. Appl. Pharmacol. 1978, 45:637-639.
24. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002, 68-69:165-175.
25. Nanji A.A., Jokelainen K., Rahemtulla A., Miao L., Fogt F., Matsumoto H., Tahan S.R., Su G.L. Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology 1999, 30:934-943.
26. Nanji A.A., Miao L., Thomas P., Rahemtulla A., Khwaja S., Zhao S., Peters D., Tahan S.R., Dannenberg A.J. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterology 1997, 112:943-951.
27. Norregaard R., Jensen B.L., Topcu S.O., Diget M., Schweer H., Knepper M.A., Nielsen S., Frokiaer J. COX-2 activity transiently contributes to increased water and NaCl excretion in the polyuric phase after release of ureteral obstruction. Am. J. Physiol. Renal Physiol. 2007, 292:F1322-1333.
28. Omogbai E.K., Ozolua R.I., Idaewor P.E., Isah A.O. Some studies on the rodenticidal action of indomethacin. Drug Chem. Toxicol. 1999, 22:629-642.
29. Osawa Y., Nagaki M., Banno Y., Yamada Y., Imose M., Nozawa Y., Moriwaki H., Nakashima S. Possible involvement of reactive oxygen species in d-galactosamine-induced sensitization against tumor necrosis factor-α-induced hepatocyte apoptosis. J. Cell. Physiol. 2001, 187:374-385.
30. Page T.H., Turner J.J., Brown A.C., Timms E.M., Inglis J.J., Brennan F.M., Foxwell B.M., Ray K.P., Feldmann M. Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. J. Immunol. 2010, 185:3694-3701.
31. Rainsford K.D. Nimesulide - a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr. Med. Res. Opin. 2006, 22:1161-1170.
32. Ramji D.P., Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 2002, 365:561-575.
33. Rothe J., Lesslauer W., Lotscher H., Lang Y., Koebel P., Kontgen F., Althage A., Zinkernagel R., Steinmetz M., Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364:798-802.
34. Silverstein R. Review: d-galactosamine lethality model: scope and limitations. J. Endotoxin Res. 2004, 10:147.
35. Tanaka A., Hase S., Miyazawa T., Takeuchi K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J. Pharmacol. Exp. Ther. 2002, 300:754-761.
36. Tipoe G.L., Leung T.M., Liong E., So H., Leung K.M., Lau T.Y., Tom W.M., Fung M.L., Fan S.T., Nanji A.A. Inhibitors of inducible nitric oxide (NO) synthase are more effective than an NO donor in reducing carbon-tetrachloride induced acute liver injury. Histol. Histopathol. 2006, 21:1157-1165.
37. Tipoe G.L., Liong E.C., Casey C.A., Donohue T.M., Eagon P.K., So H., Leung T.M., Fogt F., Nanji A.A. A voluntary oral ethanol-feeding rat model associated with necroinflammatory liver injury. Alcohol. Clin. Exp. Res. 2008, 32:669-682.
38. Traversa G., Bianchi C., Da Cas R., Abraha I., Menniti-Ippolito F., Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003, 327:18-22.
39. Wang D., Paz-Priel I., Friedman A.D. NF-kappa B p50 regulates C/EBP alpha expression and inflammatory cytokine-induced neutrophil production. J. Immunol. 2009, 182:5757-5762.